Home / Restatements / Pelthos Therapeutics Inc.
Filed 2026-08-13 路 Form 8-K 路 Accession 0001919246-26-000110 micro
Price before filing: $28.91 (2026-08-12 close, split/dividend-adjusted)
Market cap at flag: $102.5M (2026-08-13) 路 Latest: $71.3M (2026-10-16)
| Window | PTHS | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -24.1% | -1.5% | -22.6% | 2026-09-14 |
| 90 days | pending | pending | until 2026-11-11 | |
| 180 days | pending | pending | until 2027-02-09 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 4 insiders sold $104K (9 sales); 1 insider bought $1000K (2 purchases)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | Francis Knuettel II CFO, Treas & Secty | Sale | 1,500 | $26.84 | $40K | no | Form 4 |
| 2026-06-11 | Davis Todd C Director | Purchase | 35,445 | $27.80 | $986K | no | Form 4 |
| 2026-06-11 | Davis Todd C Director | Purchase | 503 | $28.73 | $14K | no | Form 4 |
| 2026-06-15 | Friedberg Ezra M Director | Sale | 224 | $27.12 | $6K | yes | Form 4 |
| 2026-06-15 | Friedberg Ezra M Director | Sale | 59 | $27.94 | $2K | yes | Form 4 |
| 2026-07-02 | Friedberg Ezra M Director | Sale | 534 | $26.03 | $14K | yes | Form 4 |
| 2026-07-02 | Friedberg Ezra M Director | Sale | 24 | $27.33 | $656 | yes | Form 4 |
| 2026-07-02 | Greenleaf Peter Director | Sale | 712 | $26.00 | $19K | yes | Form 4 |
| 2026-07-02 | Greenleaf Peter Director | Sale | 85 | $27.27 | $2K | yes | Form 4 |
| 2026-07-02 | Pauls Matthew Director | Sale | 692 | $26.00 | $18K | yes | Form 4 |
| 2026-07-02 | Pauls Matthew Director | Sale | 94 | $27.36 | $3K | yes | Form 4 |
| 2026-08-13: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-05-15 to 2026-09-12. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"On August 12, 2026, the audit committee of our board of directors (the "Audit Committee"), in consultation with management, concluded that because of a misapplication of Accounting Standards Codification ("ASC") 820, Fair Value Measurements, related to certain Level 3 fair value measurements of the Company's convertible debt, the Company's previously issued condensed consolidated financial statements in its..."
Quoted from the filing. Source
The company says previously issued financial statements (or the auditor's report on them) should no longer be relied upon (8-K Item 4.02). Non-reliance on the financial statements themselves is one of the most serious accounting red flags: past reported numbers were wrong and will be restated.
Scope: previously issued financial statements
Why this score: also within 90 days: Auditor change
Read the original filing on SEC.gov →
🔔 Get email alerts for this company
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.